-+ 0.00%
-+ 0.00%
-+ 0.00%

Allarity Therapeutics Secures US Patent for Stenoparib Dosing Regimen With Protection Into 2045

PUBT·11/18/2026 12:52:02
Allarity Therapeutics Secures US Patent for Stenoparib Dosing Regimen With Protection Into 2045
  • Allarity Therapeutics received a U.S. patent covering stenoparib treatment regimens, with protection extending into 2045.
  • The 36 allowed claims cover twice-daily oral dosing for advanced ovarian cancer and other solid tumors, including disease resistant to prior therapies.
  • The patent supports the dosing strategy used in its ongoing Phase 2 program, which it intends to advance to pivotal trials.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Allarity Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611180750PRIMZONEFULLFEED1001304273) on November 18, 2026, and is solely responsible for the information contained therein.